In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drugs from competing pharmaceuticals have been turned back by the agency.
Continue reading FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns
FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns originally appeared on DailyFinance on Tue, 01 Feb 2011 11:17:00.
Filed Under: Company News, Health Care, Stocks in the News